In early 2026, the National Institute for Health and Care Excellence (NICE) published draft guidance recommending smart insulin pens for adults with type 1 diabetes. The devices, which track doses and calculate boluses via a mobile app, have been shown to reduce severe hypoglycemia and improve glycemic control. Yet across England, local NHS formularies still list only basic insulin injectables—vials, syringes, and standard pens—leaving patients and clinicians caught between guideline recommendations and what commissioners will fund.

Guidelines Recommend Smart Pens, But Formularies Say No

The NICE draft, informed by real-world data from UK diabetes registries, concluded that smart pens can lower HbA1c by roughly 0.3–0.5% and cut the rate of severe hypoglycemic events. The committee heard patient testimonies describing how dose memory and bolus calculators helped them manage daily variability. “It’s like having a second brain,” one patient told the panel. “I used to guess my doses. Now I know exactly what I took.”

Despite this, local NHS commissioners—who hold fixed annual procurement budgets—have not added smart pens to their formularies. The devices cost around £800–1,200 per patient per year, compared with under £50 for basic pens. Trusts must balance these costs against other diabetes technology, such as continuous glucose monitors and insulin pumps, which also have proven benefits.

The discrepancy is not a rejection of the evidence but a reflection of how NHS budgeting works. There is no central ring-fenced fund for diabetes technology; each integrated care system (ICS) decides its own priorities. As a result, a patient in one region may receive a smart pen while another is told they are not available.

Clinicians report spending hours writing individual funding requests, often with inconsistent outcomes. “It’s a postcode lottery,” said Dr. Sarah Chen, a consultant diabetologist in Manchester. “I have patients who self-fund because they can’t wait for the system to catch up.”

Consider the case of a 32-year-old accountant from Leeds who experienced three severe hypoglycemic episodes in six months, one requiring an ambulance. Her diabetes team recommended a smart pen, but the local formulary only listed basic pens. After a three-month appeal process, funding was denied, and she now pays roughly £800 annually out of pocket for smart pen cartridges. Meanwhile, a similarly affected patient in London, where a pilot program exists, received a smart pen within weeks. These real-world stories illustrate the human cost of formulary variation.

The Clinical Case for Smart Pens in Type 1 Diabetes

Smart insulin pens combine a reusable injector with a smartphone app that logs doses, calculates correction boluses, and generates reports. Unlike standard pens, they provide dose memory—critical for patients who cannot recall whether they injected before a meal. The bolus calculator reduces error in adjusting for carbohydrate intake and current glucose levels.

Evidence from observational studies and small randomized trials suggests these features translate into clinical gains. A 2024 meta-analysis of six studies found a mean HbA1c reduction of 0.4% among smart pen users compared with standard therapy. The same analysis reported a roughly 30% reduction in non-severe hypoglycemic events. For patients with frequent hypos, the devices offer a practical tool to identify patterns and adjust dosing.

Patient-reported outcomes also favor smart pens. Surveys indicate higher treatment satisfaction and less diabetes distress among users. The NICE committee noted that qualitative data from focus groups described improved confidence in managing insulin doses, especially during travel or social occasions.

However, the evidence base is not without limitations. Most studies are short-term, typically 6–12 months, and few have examined long-term complications or mortality. The Cochrane review of insulin delivery devices, updated in 2025, rated the quality of evidence for smart pens as moderate, citing small sample sizes and industry sponsorship of many trials.

Cost-effectiveness modeling submitted to NICE used a 20-year time horizon and assumed a reduction in HbA1c of 0.4% sustained over that period. At the current list price, smart pens did not meet the standard threshold of £20,000–30,000 per quality-adjusted life year (QALY) gained. The incremental cost-effectiveness ratio was estimated at roughly £45,000 per QALY—above what NICE typically considers acceptable for routine NHS use.

A counter-argument often raised by health economists is that the trials enrolled highly motivated volunteers. In routine practice, adherence to the app may drop, and real-world benefits could be smaller. For instance, a 2025 observational study from Scotland found that among patients prescribed a smart pen, only about 60% used the app consistently after six months. Those who did use it saw HbA1c improvements of around 0.3%, but the non-adherent group showed no benefit. This suggests that patient selection and support are critical to achieving value.

Why Public Formularies Resist Coverage

NHS trust formularies are driven by cost containment. With diabetes spending already accounting for roughly 10% of the NHS budget, commissioners are wary of adding new devices without clear offsets elsewhere. Smart pens compete directly with pump consumables and glucose test strips for the same limited funds.

Basic insulin pens—simple, reusable, or prefilled—cost the NHS about £30–50 per patient per year. A smart pen, with its app, rechargeable battery, and proprietary cartridges, is an order of magnitude more expensive. For a trust managing thousands of patients, the cumulative cost is substantial.

Manufacturers have not offered significant discounts to the NHS. Unlike in some other countries where smart pens are bundled with glucose sensors, UK pricing remains high. Commissioners see the devices as a “nice-to-have” rather than a necessity, especially when pump therapy—which also automates dosing—is available for patients with poorly controlled diabetes.

Another barrier is the lack of a dedicated funding stream. The NHS Long Term Plan emphasized expanding access to flash glucose monitoring, which absorbed much of the available diabetes technology budget. Smart pens were not included in the initial rollout, and no central budget has since been allocated.

Regional variation is stark. Some ICS areas, such as those with strong diabetes networks and research ties, have funded small pilot programs. Others have explicitly excluded smart pens from their formularies, citing the cost-effectiveness analysis. “We can’t afford to fund everything that works,” said Mark Davies, a commissioning manager in the Midlands. “We have to prioritize interventions that deliver the most health gain per pound.”

To illustrate, the Greater Manchester pilot allocated funding for roughly 200 smart pens over 18 months, with strict eligibility criteria: patients must have had at least two severe hypoglycemic events in the past year and be willing to use the app. Early results show a 25% reduction in emergency department visits for hypoglycemia, but the sample is too small to draw firm conclusions. In contrast, the West Midlands pilot was paused after six months due to budget overruns, highlighting the fragility of local initiatives.

The Discrepancy Between Evidence and Access

The gap between what NICE recommends and what formularies fund is not unique to smart pens. Similar tensions exist for newer insulins, hybrid closed-loop systems, and even some continuous glucose monitors. But the smart pen case is particularly stark because the devices are relatively simple and low-risk compared with pumps.

Real-world adherence data may eventually shift the cost-effectiveness calculation. If patients who use smart pens have fewer hospital admissions for diabetic ketoacidosis or severe hypoglycemia, the upfront device cost could be offset. A 2025 analysis of UK primary care data found that smart pen users had 20% fewer emergency department visits for hypoglycemia, but the sample was small and confounded by higher baseline engagement.

Health economists point out that the 20-year time horizon used in NICE’s model may underestimate benefits. Improved glycemic control in early adulthood reduces the risk of retinopathy, nephropathy, and neuropathy decades later. If smart pens help patients maintain better control during the transition from pediatric to adult care, the long-term savings could be substantial.

On the other hand, critics argue that the devices may not be cost-effective in routine practice. “The clinical trials were done in highly motivated populations,” said Dr. James O’Brien, a health economist at the University of York. “In the real world, adherence to the app may drop, and the benefit may shrink.”

The NICE committee acknowledged this uncertainty. Its draft guidance included a recommendation that smart pens be considered for patients who have frequent hypoglycemia or who struggle with dose calculation, but stopped short of a universal recommendation. The final decision, expected in late 2026, may include a conditional approval for selected groups, such as those with impaired awareness of hypoglycemia.

Another layer of complexity is the interaction with other diabetes technologies. For patients already using continuous glucose monitors (CGMs), a smart pen adds relatively little incremental benefit, since the CGM already provides trend data and alarms. The real value may be for patients on multiple daily injections without CGM, where the bolus calculator and dose memory fill a gap. Commissioners are therefore considering whether to prioritize smart pens for CGM-naive patients, but this creates further inequity.

Patient Advocacy Groups Call for Parity

Diabetes UK and JDRF jointly issued a statement in early 2025 calling for equitable access to diabetes technology. “No patient should be denied a device that reduces the risk of severe hypos simply because of where they live,” the statement read. A petition launched by the two organizations gathered over 15,000 signatures within three months.

Patients have taken matters into their own hands. Online forums and social media groups share tips on how to obtain smart pens through private prescription, out-of-pocket purchase, or cross-border ordering. Some patients report spending several hundred pounds per year on smart pen cartridges, a significant burden for those on low incomes.

The inequality extends beyond geography. Younger, tech-savvy patients are more likely to request and receive smart pens, while older patients or those with digital literacy barriers may not be aware of the option. Advocacy groups have called for training programs and simplified apps to ensure equitable access.

Clinicians also face ethical dilemmas. “I have patients who would clearly benefit from a smart pen, but I can’t prescribe it because the trust won’t pay,” said Dr. Chen. “I end up spending time writing appeals that may be rejected anyway. It’s demoralizing.”

Some trusts have developed local policies to prioritize smart pens for patients with recurrent severe hypoglycemia. But these policies vary widely, and there is no national framework to ensure consistency.

A notable example is the campaign by a patient-led group in the South West, which collected over 500 patient stories of hypoglycemia-related distress and presented them to the local ICS board. The board responded by commissioning a health equity audit, which found that older adults and those from deprived areas were significantly less likely to be prescribed any diabetes technology. The audit recommended a targeted outreach program, but funding has not yet been secured.

What the NICE Final Guidance Will Mean

The final NICE appraisal is expected in late 2026, and it may include a conditional recommendation for smart pens in selected patient groups. The committee has indicated it will review updated real-world cost data from pilot programs that have started in three ICS areas: Greater Manchester, South London, and the West Midlands.

These pilots will collect data on HbA1c changes, hypoglycemia rates, hospital admissions, and patient satisfaction over 18 months. If the results show significant reductions in acute events, the cost-effectiveness estimates could improve, potentially leading to a broader recommendation.

The decision may also set a precedent for other smart devices, such as connected insulin pens for type 2 diabetes or automated insulin delivery systems. If NICE approves smart pens but formularies still resist, the tension between national guidance and local funding will intensify.

Manufacturers are watching closely. Some have hinted at price reductions if volume commitments are made, but no formal negotiations have been announced. The NHS has historically secured discounts for diabetes technologies through bulk procurement, and smart pens may follow that path.

For now, clinicians and patients are left in limbo. The draft guidance provides a clinical rationale, but without funding, it remains an aspiration. As one patient advocate put it: “NICE says we should have them. The trust says no. Who decides?”

In the meantime, some clinicians are exploring alternative strategies. For example, a diabetes clinic in Bristol has started a “technology triage” service, where patients are assessed for smart pens, pumps, and CGMs together, and the most cost-effective combination is recommended. This approach has improved patient satisfaction but has not resolved the funding gap for smart pens specifically.

Three Takeaways for Clinicians and Patients

Document hypo frequency in clinic notes. If you experience two or more severe hypoglycemic events per year, or have impaired awareness of hypoglycemia, make sure your diabetes team records this. It strengthens the case for a smart pen or pump.

Refer to a specialist diabetes team for device review. Not all clinics are equally informed about smart pens. A specialist team can assess whether a smart pen is appropriate and, in some regions, may have access to pilot programs or local funding.

Check your local formulary before promising a smart pen. Patients and clinicians alike should verify what devices are available in their area. The NHS website and trust pharmacy pages list formulary items. If smart pens are not listed, consider asking about a pump instead.

For patients who have tried multiple daily injections and still struggle with glycemic variability, insulin pumps remain the standard alternative. Smart pens are not a replacement for pumps in those who need automated insulin delivery. But for many, they offer a middle ground.

Advocate through your trust diabetes committee. Many trusts have a diabetes steering group that reviews new technologies. Patients and clinicians can submit requests for formulary additions, supported by evidence and local need.

This article is for informational purposes only and does not constitute medical advice. Individual treatment decisions should be made in consultation with a qualified healthcare professional.